arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

JOHNSON & JOHNSON

JNJ
$257.17 ▼ -0.41 (-0.16%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
20 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
76
Health
Good
Bullish
auto_awesome

Analytical Summary

JOHNSON & JOHNSON shows strong fundamentals with top-quartile Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $619.1B
Dividend Yield 2.00%
Revenue Growth 6.0%
Op. Margin None
ROIC None
FCF / Share $8.18
Trailing P/E 23.1x
Price / Book
FCF Yield 3.2%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

20-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$94.19B
↑ +6.0%
Net Income Profit after all expenses
$26.80B
↑ +90.6%
Operating Margin Operating profit as % of sales
29.0%
↑ +26.2%
FCF / Share Free cash flow per share
$8.18
↓ -0.7%
Long-Term Debt Long-term obligations
$41.44B
↑ +27.9%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
86
Cash Quality
50

Dividend History

Dividend / share · sourced from SEC filings
$5.14 Latest / share
+4.7% YoY
+5.8% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 75 quarters